drug · small molecule
patient view →mirdametinib
Phase 2updated 2mo agoby SpringWorks Therapeutics Inc🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
targets
Dual specificity mitogen-activated protein kinase kinase 1Dual specificity mitogen-activated protein kinase kinase 2
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that